Structured evidence table for Vitamin C Iron Absorption Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Vitamin C Iron Absorption Randomized Trial | Causes and contributing factors include inadequate intake, malabsorption, chronic blood loss, and increased demands related to growth, menstruation, or pregnancy [,]. | 3 | García-Erce José Antonio (2026) | Iron Deficiency and Oral Treatments: Limitations, Pharmacokinetics, and the Role of Iron Protein Succinylate in Clinical Practice |
| Vitamin C Iron Absorption Randomized Trial | During pregnancy, iron requirements triple to support fetal growth, placental function, and maternal red cell expansion [], increasing the risk of maternal morbidity, and peri- and postpartum consequences [,,]. | 3 | García-Erce José Antonio (2026) | Iron Deficiency and Oral Treatments: Limitations, Pharmacokinetics, and the Role of Iron Protein Succinylate in Clinical Practice |
| Vitamin C Iron Absorption Randomized Trial | In Europe, up to 25% of children under age three suffer from ID [], leading to impairments in attention, motor and learning development, and reduced immunity, increasing morbidity and mortality [,,]. | 3 | García-Erce José Antonio (2026) | Iron Deficiency and Oral Treatments: Limitations, Pharmacokinetics, and the Role of Iron Protein Succinylate in Clinical Practice |
| Vitamin C Iron Absorption Randomized Trial | 1 2 3 4 5 6 7 Iron deficiency (ID), defined by the World Health Organization (WHO) as a condition in which there are no mobilizable iron stores and signs of a compromised supply of iron to tissues, including the erythron, are noted [], is the most common nutritional deficiency worldwide and a major contributor to global morbidity. | 3 | García-Erce José Antonio (2026) | Iron Deficiency and Oral Treatments: Limitations, Pharmacokinetics, and the Role of Iron Protein Succinylate in Clinical Practice |
| Vitamin C Iron Absorption Randomized Trial | pylori Anemia constitutes a significant global public health problem, affecting approximately one-third of the world’s population and being associated with increased morbidity and mortality among affected individuals. | 3 | Wróblewska Joanna (2026) | Helicobacter pylori Infection and Anemia: The Potential Role of Vitamin C and Vitamin B 12 |
| Vitamin C Iron Absorption Randomized Trial | Cross-sectional studies conducted in different patient groups, including elderly individuals, children, and adults with dyspeptic symptoms, have demonstrated a significant association betweeninfection and an increased prevalence of anemia. | 3 | Wróblewska Joanna (2026) | Helicobacter pylori Infection and Anemia: The Potential Role of Vitamin C and Vitamin B 12 |
| Vitamin C Iron Absorption Randomized Trial | pylori 6 7 In the case ofinfection, disturbances in iron metabolism may result, among other mechanisms, from decreased gastric acid secretion, which limits the solubility and absorption of dietary iron, and from competition between the bacterium and the host for available iron resources. | 3 | Wróblewska Joanna (2026) | Helicobacter pylori Infection and Anemia: The Potential Role of Vitamin C and Vitamin B 12 |
| Vitamin C Iron Absorption Randomized Trial | Among the various etiologies of anemia, the most common is iron deficiency anemia (IDA), which results from insufficient intake or availability of iron necessary for proper erythropoiesis. | 3 | Wróblewska Joanna (2026) | Helicobacter pylori Infection and Anemia: The Potential Role of Vitamin C and Vitamin B 12 |
Source documents